Welcome to our dedicated page for LakeShore Biopharma Co. SEC filings (Ticker: LSB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The LakeShore Biopharma Co., Ltd (LSB) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer in the biotechnology and healthcare sector. LakeShore Biopharma files reports with the U.S. Securities and Exchange Commission, including annual reports on Form 20-F and current reports on Form 6-K, which cover financial performance, corporate actions, listing status, and material agreements.
For investors analyzing LakeShore Biopharma’s structure and corporate trajectory, recent Form 6-K filings are particularly relevant. One filing references a press release titled "LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting", documenting the suspension of trading of its ordinary shares and warrants on The Nasdaq Capital Market and the expected commencement of trading on the OTC Pink Open Market under the symbols LSBCF and LSBWF. This filing outlines Nasdaq’s determination based on non-compliance with the minimum bid price requirement and the related listing rules.
Another Form 6-K includes a press release titled "LakeShore Biopharma Enters into Definitive Agreement for Going-Private Transaction" and an Agreement and Plan of Merger among LakeShore Biopharma, Oceanpine Skyline Inc., and Oceanpine Merger Sub Inc. This document provides the formal framework for the going-private transaction with Oceanpine-affiliated entities, following earlier disclosures of preliminary and revised non-binding proposals to acquire all outstanding ordinary shares not already owned by the proposing parties.
Through its SEC filings, LakeShore Biopharma also presents detailed financial information, including discussions of non-GAAP measures such as EBITDA, Adjusted EBITDA, and adjusted net income (loss), along with reconciliations to U.S. GAAP metrics. On this page, AI-powered tools can help readers quickly interpret lengthy filings, highlight key sections related to listing changes, merger agreements, and financial metrics, and make it easier to track the evolution of LakeShore Biopharma’s regulatory and corporate profile over time.
LakeShore Biopharma Co., Ltd. director Xue Linnan has filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing establishes their status as a director and formally begins periodic ownership reporting, but does not itself reflect any buy or sell transaction.
LakeShore Biopharma Co., Ltd. director and Chief Financial Officer Yu Rui reported initial beneficial ownership of a share option covering 203,464 underlying Ordinary Shares. The option has an exercise price of $1.225 per share and expires on December 13, 2034.
According to the vesting terms, 25% of the underlying shares vest on December 31, 2024, and the remaining 75% vest in three equal annual installments on each anniversary of the December 13, 2024 grant date, subject to Yu Rui’s continued service to the company. The filing does not reflect any purchase or sale of shares, only this option holding.
LakeShore Biopharma Co., Ltd. director Pan Yue has filed an initial Form 3, which is the required first ownership report for company insiders. The filing identifies Pan Yue as a director but, in the provided data, does not show any reportable transactions or derivative positions.
LakeShore Biopharma Co., Ltd. director Shao Chunyang filed a Form 3, which is an initial statement of beneficial ownership for insiders. This filing reports no share purchases, sales, gifts, or other equity transactions and shows no derivative positions or holding entries for this reporting person.
LakeShore Biopharma Co., Ltd. filed an initial Form 3 to report the beneficial ownership status of director Zhao Jutao. The filing lists Zhao as a board member and indicates no reported transactions or holdings in either common stock or derivative securities at this time.
LakeShore Biopharma reported that its board’s special committee has received a revised, preliminary and non-binding proposal from Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. to acquire all outstanding ordinary shares they do not already own for US$0.06 per share in cash.
The bidders referenced arbitral awards totaling approximately RMB576.5 million against certain PRC subsidiaries, which they believe constitute a “Company Material Adverse Effect” under the existing November 2025 merger agreement and give them the right not to close on current terms. The special committee will evaluate the lower-priced offer, and the company stresses there is no assurance any definitive offer, agreement, or transaction will ultimately be completed.
LakeShore Biopharma’s controlling shareholder group filed Amendment No. 5 to its Schedule 13D, outlining a sharply revised going‑private proposal. The consortium now proposes to buy all publicly held ordinary shares at US$0.06 per share, compared with the prior US$0.90 offer, via equity funding and rollover of existing holdings.
The filing cites arbitral awards imposing approximately RMB576.5 million of monetary liabilities and related litigation uncertainty as key reasons for the lower price, warning these could materially weaken the company’s financial condition. If completed, the merger would take LakeShore private, terminate SEC registration and remove its shares from the OTC Pink market. The proposal remains non‑binding, with no assurance that definitive agreements or a transaction will be consummated.
LakeShore Biopharma reports that the buyer group for its previously announced going‑private deal at $0.90 per share has sent a notice claiming a “Company Material Adverse Effect” under the merger agreement.
The claim is based on arbitral awards that created an approximate RMB576,500,000 financial liability. Citing this, the buyer group asserts it has the right not to consummate the merger and says it will not attend or vote at the extraordinary general meeting that was scheduled for February 12, 2026. In response, the company has postponed the meeting indefinitely and will disregard any previously submitted proxy cards, while it reviews the buyer group’s position and its own options.
LakeShore Biopharma’s buyer group has determined that recent arbitration awards mean its planned merger cannot proceed on current terms. Three awards from the Kaifeng Arbitration Commission require certain PRC subsidiaries to pay about RMB576.5 million, which the group believes causes a “Company Material Adverse Effect” under the merger agreement.
Because this condition to closing can no longer be met, the buyer group has notified the company it will not proceed with closing and its members will not attend or vote at the February 12, 2026 extraordinary general meeting. The group, however, plans to discuss potential amended transaction terms with the issuer.